Prognostic value of primary tumor sidedness in patients with non-metastatic IBD related CRC - Is it the exception to the rule?
CRC
IBD
Tumor laterality
Journal
Surgical oncology
ISSN: 1879-3320
Titre abrégé: Surg Oncol
Pays: Netherlands
ID NLM: 9208188
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
01
05
2022
revised:
22
09
2022
accepted:
04
10
2022
pubmed:
19
10
2022
medline:
7
12
2022
entrez:
18
10
2022
Statut:
ppublish
Résumé
Although primary tumor sidedness (PTS) has a known prognostic role in sporadic colorectal cancer (CRC), its role in Inflammatory Bowel Disease related CRC (IBD-CRC) is largely unknown. Thus, we aimed to evaluate the prognostic role of PTS in patients with IBD-CRC. All eligible patients with surgically treated, non-metastatic IBD-CRC were retrospectively identified from institutional databases at ten European and Asian academic centers. Long term endpoints included recurrence-free (RFS) and overall survival (OS). Multivariable Cox proportional hazard regression as well as propensity score analyses were performed to evaluate whether PTS was significantly associated with RFS and OS. A total of 213 patients were included in the analysis, of which 32.4% had right-sided (RS) tumors and 67.6% had left-sided (LS) tumors. PTS was not associated with OS and RFS even on univariable analysis (5-year OS for RS vs LS tumors was 68.0% vs 77.3%, respectively, p = 0.31; 5-year RFS for RS vs LS tumors was 62.8% vs 65.4%, respectively, p = 0.51). Similarly, PTS was not associated with OS and RFS on propensity score matched analysis (5-year OS for RS vs LS tumors was 82.9% vs 91.3%, p = 0.79; 5-year RFS for RS vs LS tumors was 85.1% vs 81.5%, p = 0.69). These results were maintained when OS and RFS were calculated in patients with RS vs LS tumors after excluding patients with rectal tumors (5-year OS for RS vs LS tumors was 68.0% vs 77.2%, respectively, p = 0.38; 5-year RFS for RS vs LS tumors was 62.8% vs 59.2%, respectively, p = 0.98). In contrast to sporadic CRC, PTS does not appear to have a prognostic role in IBD-CRC.
Sections du résumé
BACKGROUND
BACKGROUND
Although primary tumor sidedness (PTS) has a known prognostic role in sporadic colorectal cancer (CRC), its role in Inflammatory Bowel Disease related CRC (IBD-CRC) is largely unknown. Thus, we aimed to evaluate the prognostic role of PTS in patients with IBD-CRC.
METHODS
METHODS
All eligible patients with surgically treated, non-metastatic IBD-CRC were retrospectively identified from institutional databases at ten European and Asian academic centers. Long term endpoints included recurrence-free (RFS) and overall survival (OS). Multivariable Cox proportional hazard regression as well as propensity score analyses were performed to evaluate whether PTS was significantly associated with RFS and OS.
RESULTS
RESULTS
A total of 213 patients were included in the analysis, of which 32.4% had right-sided (RS) tumors and 67.6% had left-sided (LS) tumors. PTS was not associated with OS and RFS even on univariable analysis (5-year OS for RS vs LS tumors was 68.0% vs 77.3%, respectively, p = 0.31; 5-year RFS for RS vs LS tumors was 62.8% vs 65.4%, respectively, p = 0.51). Similarly, PTS was not associated with OS and RFS on propensity score matched analysis (5-year OS for RS vs LS tumors was 82.9% vs 91.3%, p = 0.79; 5-year RFS for RS vs LS tumors was 85.1% vs 81.5%, p = 0.69). These results were maintained when OS and RFS were calculated in patients with RS vs LS tumors after excluding patients with rectal tumors (5-year OS for RS vs LS tumors was 68.0% vs 77.2%, respectively, p = 0.38; 5-year RFS for RS vs LS tumors was 62.8% vs 59.2%, respectively, p = 0.98).
CONCLUSIONS
CONCLUSIONS
In contrast to sporadic CRC, PTS does not appear to have a prognostic role in IBD-CRC.
Identifiants
pubmed: 36257179
pii: S0960-7404(22)00169-4
doi: 10.1016/j.suronc.2022.101874
pmc: PMC10266238
mid: NIHMS1894894
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101874Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest None.
Références
JAMA Oncol. 2017 Feb 01;3(2):211-219
pubmed: 27787550
Ann Surg Oncol. 2020 Dec;27(13):4864-4866
pubmed: 32959141
Int J Colorectal Dis. 2021 Aug;36(8):1731-1737
pubmed: 33712904
Tech Coloproctol. 2019 Jan;23(1):3-13
pubmed: 30701345
Semin Immunol. 2017 Aug;32:3-13
pubmed: 28465070
Sci Rep. 2020 Oct 21;10(1):17900
pubmed: 33087797
Gastroenterology. 2011 May;140(6):1807-16
pubmed: 21530747
Inflamm Bowel Dis. 2009 Apr;15(4):630-8
pubmed: 18942763
Ann Surg. 2010 Aug;252(2):330-5
pubmed: 20622662
Br J Cancer. 2003 Jul 21;89(2):232-8
pubmed: 12865907
Oncotarget. 2017 Mar 28;8(13):22175-22186
pubmed: 28077799
Br J Surg. 2019 Dec;106(13):1747-1760
pubmed: 31386192
Eur J Cancer. 2019 Apr;111:1-7
pubmed: 30797014
Gastroenterology. 2013 Jul;145(1):166-175.e8
pubmed: 23541909
J Gastrointest Oncol. 2018 Apr;9(2):263-268
pubmed: 29755764
Gastroenterol Hepatol (N Y). 2018 Jan;14(1):19-25
pubmed: 29491757
Am J Physiol Gastrointest Liver Physiol. 2004 Jul;287(1):G7-17
pubmed: 15194558
Ann Surg. 2021 Jun 1;273(6):1165-1172
pubmed: 31389831
J Surg Oncol. 2021 Mar;123(4):1005-1014
pubmed: 33368279
Nat Rev Gastroenterol Hepatol. 2009 May;6(5):297-305
pubmed: 19404270
Clin Transl Gastroenterol. 2016 Nov 3;7(11):e200
pubmed: 27811909
J Surg Oncol. 2016 Dec;114(7):803-809
pubmed: 27792291
J Gastrointest Surg. 2016 Mar;20(3):648-55
pubmed: 26573851
Semin Immunopathol. 2013 Mar;35(2):229-44
pubmed: 23161445
J Clin Oncol. 2011 Nov 20;29(33):4401-9
pubmed: 21969498
Life Sci. 2017 Jul 1;180:60-67
pubmed: 28506682
Gastroenterology. 2016 Apr;150(4):931-43
pubmed: 26764183
JAMA Oncol. 2017 Jul 1;3(7):1000
pubmed: 28418502